Core Insights - Bayer's new patented ingredient, Tiannmingduo®630, is the first inhibitor based on human tyrosinase screening, aimed at suppressing melanin production from the source [1][3] - The introduction of the Chinese trademark signifies the ingredient's localization for Chinese consumers and strengthens intellectual property protection [3] - Tiannmingduo®630 is a result of over 20 years of research and development, reflecting the strategy of "driving global R&D with Chinese demand" [3] Product Launch and Market Strategy - Bayer has launched 12 products containing Tiannmingduo®630, covering various skincare segments including mass market, dermatological, high-end skincare, and professional medical aesthetics [1] - The ingredient received approval as the first new whitening ingredient under the Cosmetic Supervision and Administration Regulations, indicating a significant regulatory milestone [4] - The second-generation light-activated essence featuring Tiannmingduo®630 was globally launched in Shanghai, marking a transition from cross-border to local sales [4] Research and Development - The development of Tiannmingduo®630 involved overcoming challenges in expressing recombinant human tyrosinase over 15 years, screening from over 50,000 molecules [3] - The ingredient has completed a full set of toxicological safety assessments and has been published in multiple SCI papers [3] Regulatory and Industry Support - The ingredient's market entry was facilitated by supportive policies, including the establishment of a synchronized application mechanism for new raw materials and related products [4] - Bayer emphasizes data-driven claims in the competitive beauty market and intends to combat false advertising related to unverified ingredients [4]